Role of biomarkers in developing new therapies for vascular disease.
The use of biomarkers has been among the advances that have helped in the better medical management of patients. Biomarkers such as total cholesterol, low-density lipoprotein cholesterol, and hemoglobin A1c are used routinely. Advances in technologies, proteomics, and genomics and the resultant improved understanding of the pathophysiology of vascular diseases have led to the identification of several promising biomarkers. These biomarkers may be used to identify specific populations that may benefit from therapies, as surrogate markers of clinical efficacy, or as targets of therapy.
Nambi
Vijay
V
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, 6565 Fannin, M.S. A-601, Houston, Texas 77030, USA.
Ballantyne
Christie M
CM
D015415:Biomarkers; D002097:C-Reactive Protein / Q000502:physiology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D023381:Endpoint Determination; D005544:Forecasting; D023281:Genomics; D006801:Humans; D008967:Molecular Biology / Q000379:methods; D018579:Patient Selection; D010741:Phospholipases A / Q000502:physiology; D011237:Predictive Value of Tests; D040901:Proteomics; D015203:Reproducibility of Results; D012107:Research Design; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014652:Vascular Diseases / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*
D015415:Biomarkers; D002097:C-Reactive Protein; D010741:Phospholipases A